


Data Sheet

Product Name:	Isorhamnetin
Cat. No.:	CS-5945
CAS No.:	480-19-3
Molecular Formula:	C ₁₆ H ₁₂ O ₇
Molecular Weight:	316.26
Target:	Endogenous Metabolite; MEK; PI3K
Pathway:	MAPK/ERK Pathway; Metabolic Enzyme/Protease; PI3K/Akt/mTOR
Solubility:	DMSO : 100 mg/mL (316.20 mM; Need ultrasonic)



BIOLOGICAL ACTIVITY:

Isorhamnetin is a flavonoid compound extracted from the Chinese herb Hippophae rhamnoides L.. Isorhamnetin suppresses skin cancer through direct inhibition of **MEK1** and **PI3K**. IC₅₀ & Target: MEK1^[1]

PI3K^[1] In Vitro: Isorhamnetin is a plant flavonoid that occurs in fruits and medicinal herbs. Isorhamnetin binds directly to MEK1 in an ATP-noncompetitive manner and to PI3-K in an ATP-competitive manner. In vitro and ex vivo kinase assay data show that Isorhamnetin inhibits the kinase activity of MAP/ERK kinase (MEK) 1 and PI3-K and the inhibition is due to direct binding with Isorhamnetin^[1]. Isorhamnetin inhibits the Akt/mTOR and MEK/ERK signaling pathways, and promotes the activity of the mitochondrial apoptosis signaling pathway. The inhibitory effects of Isorhamnetin on breast cancer cells are determined using the CCK-8 method. Isorhamnetin inhibits the proliferation of numerous breast cancer cells (IC₅₀, ~10 μM), including MCF7, T47D, BT474, BT-549, MDA-MB-231 and MDA-MB-468, whereas less inhibitory activity is observed in the MCF10A normal breast epithelial cell line (IC₅₀, 38 μM)^[2]. **In Vivo:** Photographic data shows that Isorhamnetin treatment suppresses tumor development in mice. The average volume of tumors in untreated mice increases over time and reaches a volume of 623 mm³ at 4 weeks post-inoculation; however, at this time, in mice treated with 1 or 5 mg/kg Isorhamnetin, the average tumor volume is only 280 or 198 mm³, respectively. At the end of the study, Isorhamnetin treatment (1 or 5 mg/kg) reduces tumor weight compared with the untreated control group^[1].

PROTOCOL (Extracted from published papers and Only for reference)

Cell Assay: ^[2]MCF7, T47D, BT474, BT-549, MDA-MB-231 and MDA-MB-468 breast cancer cell lines, as well as a MCF10A normal breast epithelial cell line (control) are seeded into 96-well plates at a density of 5×10³ cells/well in 100 μL DMEM and placed in cell incubator for 12 h at 37°C in an atmosphere containing 5% CO₂. The cells are then treated with various concentrations of **Isorhamnetin (100, 33.3, 11.1, 3.7, 1.2, 0.4 and 0 μM) for 48 h**, and cell proliferation rates are determined by adding 10 μL CCK-8 solution prior to incubation at 37°C for 2 h. The absorbance is measured at a wavelength of 450 nm using a SpectraMax 190 Microplate Reader. For each assay, four parallel wells are included, and the half maximal inhibitory concentration (IC₅₀) is measured using the inhibition curve and presented as the mean of three independent experiments^[2].

Animal Administration: Isorhamnetin is prepared in 40% DMSO/PBS buffer (Mice)^[1].^[1]Mice^[1]

Female athymic nude mice are injected subcutaneously in the flank with A431 cells (1×10⁶ cells in 50 μL of medium and 50 μL of Matrigel). Cells are allowed to form tumors, and once the tumors reach a size of 40 mm³, the mice are randomly assigned into groups (6 mice/group) and treated with (1 or 5 mg/kg body weight) or without **Isorhamnetin** in 40% DMSO/PBS buffer, administered **intraperitoneally every other day for 28 days**. Tumor size is measured every week with calipers, and the tumor volume is calculated. Mice are sacrificed after 28 days of treatment when the control tumors reach approximately 600 mm³. The tumors are harvested, photographed, and weighed. Tumor tissues are used for western blot analysis and immunohistochemical analysis.

References:

- [1]. Kim JE, et al. Isorhamnetin suppresses skin cancer through direct inhibition of MEK1 and PI3-K. *Cancer Prev Res (Phila)*. 2011 Apr;4(4):582-91.
- [2]. Hu S, et al. Isorhamnetin inhibits cell proliferation and induces apoptosis in breast cancer via Akt and mitogen activated protein kinase kinase signaling pathways. *Mol Med Rep*. 2015 Nov;12(5):6745-51.

CAIndexNames:

4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(4-hydroxy-3-methoxyphenyl)-

SMILES:

O=C1C(O)=C(C2=CC=C(O)C(OC)=C2)OC3=CC(O)=CC(O)=C13

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 610-426-3128

Fax: 888-484-5008

E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA